One of the most exciting new therapies for cancer involves the use of autologous T cells that
are engineered to recognize and destroy cancerous cells. Patients with previously …

The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma
worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high …

Simple Summary Chimeric antigen receptor (CAR)-T cell therapy has been highly
successful in treating hematological malignancies like leukemia and lymphoma, leading to …

Adoptive cell transfer (ACT) has long been at the forefront of the battle with cancer that
began last century with the therapeutic application of tumor-infiltrating lymphocytes (TILs) …

Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite
the progress in drug development, the occurrence of microbial resistance is still a significant …

“Functional cure” is being pursued as the ultimate endpoint of antiviral treatment in chronic
hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs …

A couple of molecular-targeting medications, such as Lenvatinib, are available for the
treatment of hepatocellular carcinoma (HCC) in addition to Sorafenib in an advanced stage …

The currently recommended treatment for chronic hepatitis B virus (HBV) infection achieves
only viral suppression whilst on therapy, but rarely hepatitis B surface antigen (HBsAg) loss …

Immunotherapy treatments aim to modulate the host's immune response to either mitigate it
in inflammatory/autoimmune disease or enhance it against infection or cancer. Among …

For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of
researchers seeking to find novel immunotherapies to treat cancer. CARs were first …